Abstract
Several radiolanthanides find their application in nuclear medicine because of their favorable decay properties,
the most important ones being 143Pr, 149Pm, 153Sm, 165Dy, 161Tb, 166Ho, 169Er, 170Tm and 177Lu.
These radiolanthanides can be efficiently produced via neutron irradiation in a high-flux nuclear research
reactor. Radiochemical processing of the irradiated target is required to obtain the required purity or to
remove redundant target material. Long-lived impurities can be removed to extend the expiration time of
carrier added radiolanthanides, whereas non-carrier added radiolanthanides with high radionuclidic purity
and high specific activities can be obtained for targeted radiotherapy. Transport and distribution criteria
might become more flexible, helping to safeguard the supply of radiolanthanides for medical
purposes. Valuable and expensive target material can be regenerated after separation of the medical radiolanthanide.
Different radiochemical separation processes are discussed which are able to separate two
adjacent lanthanides, with a focus on those techniques making use of the underlying coordination
chemistry.
Details
Original language | English |
---|
Pages (from-to) | 103-125 |
---|
Number of pages | 23 |
---|
Journal | Coordination Chemistry Reviews |
---|
Volume | 382 |
---|
DOIs | |
---|
Publication status | Published - 1 Mar 2019 |
---|